Filtered By:
Source: The American Journal of Cardiology
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 336 results found since Jan 2013.
Comparison of In-Hospital Outcomes After Insertion of Watchman Device in Men Versus Women (from the National Inpatient Data)
This study aimed to analyze the National Inpatient Sample (NIS) data to evaluate gender disparities and further assess its impact on medical decision-making. The NIS data for 16,505 patients who underwent left atrial appendage occlusion with the Watchman device from 2016 to 2017 was used to perform a cross-sectional analysis.
Source: The American Journal of Cardiology - August 22, 2022 Category: Cardiology Authors: Jay Shah, Amir Khan, Ghulam Mujtaba Ghumman, Kritika Luthra, Ma'en Al-Dabbas, Muhammad Ahsan, Muhammad Shayan Khan, Mohammed Taleb, Hemindermeet Singh, Syed Sohail Ali Source Type: research
Usefulness of Self-Reported Physical Activity and Clinical Outcomes in Older Patients With Atrial Fibrillation
Current guidelines encourage regular physical activity (PA) to gain cardiovascular health benefit. However, little is known about whether older adults with atrial fibrillation (AF) who engage in the guideline-recommended level of PA are less likely to experience clinically relevant outcomes. We did a retrospective study based on the data from Systemic Assessment of Geriatric Elements in AF (SAGE-AF) prospective cohort study. The study population consisted of older participants with AF ( ≥65 years) and a congestive heart failure, hypertension, age, diabetes, stroke vascular disease, age 65 to 75 and sex(CHA2DS2-VASc) score ≥2.
Source: The American Journal of Cardiology - August 16, 2022 Category: Cardiology Authors: Qiying Dai, Jordy Mehawej, Jane S. Saczynski, Khanh-Van Tran, Hawa O. Abu, Darleen Lessard, Andreas Fillippaios, Tenes Paul, Essa Hariri, Weijia Wang, Mayra Tisminetzky, Apurv Soni, Sakeina Howard-Wilson, Molly E. Waring, Robert J. Goldberg, David D. McMa Source Type: research
Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention
The clinical significance of the CHADS2 score remains unclear in patients with coronary artery disease (CAD) without atrial fibrillation (AF). Therefore, the purpose of this study was to evaluate the association between the CHADS2 score and the long-term risk of ischemic stroke and its severity in patients with CAD with and without AF. Using the CREDO (Coronary Revascularization Demonstrating Outcome study)-Kyoto Registry Cohort-3, the present study population consisted of 11,516 patients with CAD who underwent percutaneous coronary intervention without oral anticoagulants at discharge.
Source: The American Journal of Cardiology - August 13, 2022 Category: Cardiology Authors: Yuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, Yodo Tamaki, Moriaki Inoko, Ryusuke Nishikawa, Kazuhisa Kaneda, Ko Yamamoto, Yasuaki Takeji, Akihiro Komasa, Kyohei Yamaji, Satoshi Shizuta, Tomohisa Tada, Kazuya Nagao, Satoru Suwa, Toshihiro Tamura, Hiroki Source Type: research
CHA2DS2-VASc Score, Mortality and Acute Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation
Patients with atrial fibrillation (AF) are at increased cardiovascular risk. The CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke, vascular disease, age 65 to 74 years, female gender) has been used to predict thromboembolic risk in patients with nonvalvular AF. We aimed to evaluate the association between the CHA2DS2-VASc score and the risk of acute myocardial infarction (AMI) a nd all-cause mortality in patients with AF treated with direct oral anticoagulants (DOACs).
Source: The American Journal of Cardiology - August 12, 2022 Category: Cardiology Authors: Mustafa Gabarin, Tzipi Hornik-Lurie, Saar Minha, Alexander Omelchenko, Rami Barashi, Ziad Arow, Abid Assali, David Pereg Source Type: research
Controlled Level and Variability of Systolic Blood Pressure on the Risk of Thromboembolic Events in Atrial Fibrillation and Hypertension
Hypertension is an independent risk factor for thromboembolic events in patients with atrial fibrillation (AF). However, the association between blood pressure (BP) control and thromboembolic events remains under-evaluated in patients with AF. We aimed to identify the relation between BP control and the risk of ischemic stroke and systemic embolism in hypertensive patients with AF. Data on 13,712 consecutive patients with AF (9,505 with and 4,207 without hypertension) were retrospectively analyzed.
Source: The American Journal of Cardiology - August 5, 2022 Category: Cardiology Authors: Minsoo Kim, Min Soo Cho, Gi-Byoung Nam, Ungjeong Do, Jun Kim, Kee-Joon Choi Source Type: research
Ventricular Septal Myectomy Decreases Long-Term Risk for Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy
Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) and is an important cause of morbidity and embolic stroke. The impact of outflow obstruction and the influence of surgical septal myectomy on the development of new-onset AF has not been well described. Consecutive patients with HCM without previous AF were followed for 5.0 ± 3.6 years for new-onset AF, including 717 with obstruction who did not undergo surgical myectomy (outflow gradients ≥30 mm Hg at rest or after provocation), 555 with nonobstructive HCM (outflow gradients
Source: The American Journal of Cardiology - July 11, 2022 Category: Cardiology Authors: Ethan J. Rowin, Craig Cooper, Richard T. Carrick, Melissa Tsoi, Barry J. Maron, Martin S. Maron Source Type: research
Effect of Sodium-Glucose Cotransporter Inhibitors on Major Adverse Cardiovascular Events and Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus and Atrial Fibrillation
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to lower cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular risks. Here, we aimed to evaluate the effect of SGLT2 inhibitors on major adverse cardiovascular events (MACE), a composite of cardiovascular mortality, myocardial infarction, or ischemic stroke and hospitalization for heart failure in patients with T2DM and atrial fibrillation (AF). Using the Korean National Health Insurance Service database, we identified 40,268 patients with T2DM and AF who were newly prescribed oral hypoglycemic drugs ...
Source: The American Journal of Cardiology - July 7, 2022 Category: Cardiology Authors: Chang Hee Kwon, Ye-Jee Kim, Min-Ju Kim, Myung-Jin Cha, Min Soo Cho, Gi-Byoung Nam, Kee-Joon Choi, Jun Kim Source Type: research
Intermediate-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients With a History of Atrial Fibrillation
Patients who underwent transcatheter aortic valve implantation (TAVI) with a history of atrial fibrillation (AF) have higher rates of all-cause mortality, inpatient complications, and length of hospitalization.1 –3 However, intermediate-term outcomes and the impact of stroke risk as calculated by CHA2DS2-VASc scores in the AF population who underwent TAVI have not previously been described. We aimed to evaluate intermediate-term outcomes in patients who underwent TAVI with a history of AF as stratified by CHA2DS2-VASc scores.
Source: The American Journal of Cardiology - July 4, 2022 Category: Cardiology Authors: Craig C. Morris, Kris Kumar, Ashraf Samhan, Philip Blatt, Tessa Herman, Trisha Chau, Gurion Lantz, Scott M. Chadderdon, Howard K. Song, Firas E. Zahr, Harsh Golwala Source Type: research
Comparison of Dabigatran Versus Warfarin Treatment for Prevention of New Cerebral Lesions in Valvular Atrial Fibrillation
Warfarin is the standard anticoagulation therapy for valvular atrial fibrillation (AF); however, new oral anticoagulants have emerged as an alternative. We compared the efficacy and safety of dabigatran with conventional treatment in AF associated with left-sided valvular heart disease (VHD), including mitral stenosis (MS). Patients with AF and left-sided VHD were randomly assigned to receive dabigatran or conventional treatment. The primary end point was the occurrence of clinical stroke or a new brain lesion (silent brain infarct and microbleed) on 1-year follow-up brain magnetic resonance imaging.
Source: The American Journal of Cardiology - May 9, 2022 Category: Cardiology Authors: Min Soo Cho, Minsu Kim, Seung-ah Lee, Sahmin Lee, Dae-Hee Kim, Jun Kim, Jong-Min Song, Gi-Byoung Nam, Sang Joon Kim, Duk-Hyun Kang, Kee-Joon Choi Source Type: research
Relation of Hemoglobin A1C Levels to Risk of Ischemic Stroke and Mortality in Patients With Diabetes Mellitus and Atrial Fibrillation
This study aimed to assess the incidence and risks of ischemic stroke and mortality according to baseline HbA1c levels in patients with DM and AF. We conducted a cohort study using Clalit Health Services electronic medical records. The study population included all Clalit Health Services members aged ≥25 years, with the first diagnosis of AF between January 1, 2010, and December 31, 2016, who had a diagnosis of DM.
Source: The American Journal of Cardiology - March 29, 2022 Category: Cardiology Authors: Louise Kezerle, Moti Haim, Amichay Akriv, Adi Berliner Senderey, Asaf Bachrach, Maya Leventer-Roberts, Meytal Avgil Tsadok Source Type: research
Derivation and Validation of a Clinical Score for Predicting Postoperative Atrial Fibrillation in Noncardiac Elective Surgery (the HART Score)
Postoperative atrial fibrillation (POAF) represents the most frequent cardiac arrhythmia in the surgical setting. It affects almost 3% of all patients over 45 years old who underwent noncardiovascular surgery and is associated with a higher risk of stroke, heart failure, myocardial infarction, and cardiac arrest. The study aimed to assess independent predictors of POAF and derive and validate a score for risk prediction in clinical practice. This was a retrospective cohort study including all consecutive candidates to all types of noncardiac elective surgery attending a cardiological preoperative assessment from 2016 to 2019.
Source: The American Journal of Cardiology - February 23, 2022 Category: Cardiology Authors: Giulia Stronati, Carlo Mondelli, Alessia Urbinati, Giuseppe Ciliberti, Alessandro Barbarossa, Paolo Compagnucci, Michela Casella, Antonio Dello Russo, Federico Guerra Source Type: research
Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation
Short-term outcomes are worse for patients with acute coronary syndrome (ACS) with a history of nonvalvular atrial fibrillation (NVAF). However, long-term prognosis remains unclear. We linked administrative health databases to identify patients hospitalized with ACS (ST-elevation myocardial infarction [STEMI], non –STEMI [NSTEMI], and unstable angina) between 2008 and 2019 in Alberta, Canada. Patients were stratified according to history of NVAF before hospitalization. The primary outcome was a composite of all-cause mortality, hospitalization for myocardial infarction, or stroke at 3 years.
Source: The American Journal of Cardiology - January 7, 2022 Category: Cardiology Authors: Pishoy Gouda, Douglas C. Dover, Anamaria Savu, Kevin Bainey, Shaun G. Goodman, Robert Welsh, Padma Kaul, Roopinder Kaur Sandhu Source Type: research
Meta-Analysis of Surgical Left Atrial Appendage Occlusion During Cardiac Surgery
We congratulate Mohamed et al1 on their meta-analysis of randomized controlled trials (RCTs) comparing surgical left atrial appendage occlusion (LAAO) to no LAAO in patients with atrial fibrillation (AF). The pooled estimate of a 33% reduction in risk of stroke or systemic embolism with LAAO (5 trials, 5,128 patients, risk ratio [RR] 0.67, 95% confidence interval [CI] 0.53 to 0.84, p
Source: The American Journal of Cardiology - January 5, 2022 Category: Cardiology Authors: Gwen E. Eagle, Richard P. Whitlock, Emilie P. Belley-C ôté Source Type: research
Meta-Analysis Comparing Apixaban Versus Rivaroxaban for Management of Patients With Nonvalvular Atrial Fibrillation
To compare the efficacy and safety of apixaban and rivaroxaban for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF) by way of a meta-analysis informed by real-world evidence. Systematic review and meta-analysis of observational studies including patients with NVAF on apixaban and rivaroxaban, which reported stroke/systemic embolism and/or major bleeding. Prospero registration number: CRD42021251719. Estimates of relative treatment effect (based on hazard ratios[HRs]) were pooled using the inverse variance method.
Source: The American Journal of Cardiology - December 20, 2021 Category: Cardiology Authors: Mamas A. Mamas, Sarah Batson, Kevin G. Pollock, Sarah Grundy, Andrew Matthew, Chris Chapman, Joana Assis Manuel, Usman Farooqui, Stephen A. Mitchell Source Type: research
Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs
Real-world studies have evaluated the use of anticoagulants in obese patients with nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of diagnosis codes on claims to define obesity. This retrospective study used body weight data of ≥100 kg or a body mass index of ≥30 kg/m2 to identify elderly (aged ≥65 years) NVAF patients with obesity in dually enrolled Veterans Affairs and fee-for-service Medicare patients. It evaluated the risk of stroke/systemic embolism (SE) and major bleeding (MB) in patients that initiated apixaba n versus warfarin.
Source: The American Journal of Cardiology - December 18, 2021 Category: Cardiology Authors: Steve Deitelzweig, Janvi Sah, Amiee Kang, Cristina Russ, Madison Preib, Amol D. Dhamane, Anna Ratiu, Matthew Cato, Tamuno Alfred, Edi Levi, Manuela Di Fusco Source Type: research
